| 1 | Differential methylation analysis in neuropathologically confirmed dementia with Lewy bodies | 4.6 | 5 | Citations (PDF) |
| 2 | Wrist‐worn actigraphy in agitated late‐stage dementia patients: A feasibility study on digital inclusion | 0.7 | 13 | Citations (PDF) |
| 3 | Grey matter networks in women and men with dementia with Lewy bodies | 7.5 | 4 | Citations (PDF) |
| 4 | Long-Term Dementia Risk in Parkinson Disease | 1.2 | 47 | Citations (PDF) |
| 5 | Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research | 13.9 | 0 | Citations (PDF) |
| 6 | Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample | 1.9 | 19 | Citations (PDF) |
| 7 | Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment | 0.5 | 2 | Citations (PDF) |
| 8 | Regression-based cognitive change norms applied in biochemically defined predementia Alzheimer’s disease. | 2.7 | 10 | Citations (PDF) |
| 9 | The cognitive profile of middle‐aged and older adults with high vs. low autistic traits | 5.1 | 22 | Citations (PDF) |
| 10 | MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies | 7.5 | 21 | Citations (PDF) |
| 11 | Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study | 7.5 | 2 | Citations (PDF) |
| 12 | Muscle Volume and Intramuscular Fat of the Tongue Evaluated With MRI Predict Malnutrition in People Living With Dementia: A 5-Year Follow-up Study | 3.6 | 12 | Citations (PDF) |
| 13 | Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroupsBrain, 2022, 145, 1757-1762 | 8.9 | 50 | Citations (PDF) |
| 14 | Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias | 3.7 | 18 | Citations (PDF) |
| 15 | Risky drinking and cognitive impairment in community residents aged 50 and over | 2.7 | 8 | Citations (PDF) |
| 16 | Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies | 13.0 | 91 | Citations (PDF) |
| 17 | The neuropsychiatry of Parkinson's disease: advances and challenges | 12.9 | 353 | Citations (PDF) |
| 18 | Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities | 27.5 | 148 | Citations (PDF) |
| 19 | Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology | 3.5 | 25 | Citations (PDF) |
| 20 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum | 13.0 | 220 | Citations (PDF) |
| 21 | Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts | 2.3 | 7 | Citations (PDF) |
| 22 | Traumatic life experiences and post‐traumatic stress symptoms in middle‐aged and older adults with and without autistic traits | 2.4 | 27 | Citations (PDF) |
| 23 | Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data | 6.8 | 18 | Citations (PDF) |
| 24 | Tongue muscle mass is associated with total grey matter and hippocampal volumes in Dementia with Lewy Bodies | 3.7 | 4 | Citations (PDF) |
| 25 | Actions to be taken for improving functional prognosis in dementia | 0.8 | 2 | Citations (PDF) |
| 26 | Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts – ERRATUM | 2.3 | 0 | Citations (PDF) |
| 27 | Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography | 2.4 | 3 | Citations (PDF) |
| 28 | Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases | 3.3 | 22 | Citations (PDF) |
| 29 | Light, sleep‐wake rhythm, and behavioural and psychological symptoms of dementia in care home patients: Revisiting the sundowning syndrome | 2.4 | 23 | Citations (PDF) |
| 30 | New insights into the genetic etiology of Alzheimer’s disease and related dementias | 26.1 | 1,927 | Citations (PDF) |
| 31 | Specific depressive symptoms are related with different patterns of alcohol use in community-dwelling older adults | 3.7 | 7 | Citations (PDF) |
| 32 | Prodromal Dementia With Lewy Bodies and Recurrent Panic Attacks as the First Symptom: A Case Report | 2.5 | 8 | Citations (PDF) |
| 33 | Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson’s Disease | 3.7 | 5 | Citations (PDF) |
| 34 | Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations | 13.1 | 18 | Citations (PDF) |
| 35 | Body mass index trajectories and associations with cognitive decline in people with Lewy body dementia and Alzheimer's disease | 1.9 | 12 | Citations (PDF) |
| 36 | Are subtypes of affective symptoms differentially associated with change in cognition over time: A latent class analysis | 4.8 | 8 | Citations (PDF) |
| 37 | Frailty in Parkinson's disease and its association with early dementia: A longitudinal study | 1.8 | 16 | Citations (PDF) |
| 38 | Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging | 2.7 | 48 | Citations (PDF) |
| 39 | Self-harm and Suicidality Experiences of Middle-Age and Older Adults With vs. Without High Autistic Traits | 2.3 | 20 | Citations (PDF) |
| 40 | Protocol for Rhapsody: a longitudinal observational study examining the feasibility of speech phenotyping for remote assessment of neurodegenerative and psychiatric disorders | 2.0 | 8 | Citations (PDF) |
| 41 | Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer’s Disease in Nordic Populations | 2.7 | 11 | Citations (PDF) |
| 42 | Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease | 7.5 | 47 | Citations (PDF) |
| 43 | Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011–2022 Update | 3.5 | 73 | Citations (PDF) |
| 44 | The Mental and Physical Health Profiles of Older Adults Who Endorse Elevated Autistic Traits | 2.9 | 29 | Citations (PDF) |
| 45 | The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory | 2.9 | 12 | Citations (PDF) |
| 46 | The association between aspects of carer distress and time until nursing home admission in persons with Alzheimer’s disease and dementia with Lewy bodies | 1.0 | 17 | Citations (PDF) |
| 47 | Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia With Lewy Bodies | 1.0 | 22 | Citations (PDF) |
| 48 | Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson’s Disease Living in the United Kingdom | 3.7 | 23 | Citations (PDF) |
| 49 | Mild Cognitive Impairment: the Manchester consensus | 1.8 | 176 | Citations (PDF) |
| 50 | Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes | 3.8 | 20 | Citations (PDF) |
| 51 | Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns | 4.9 | 70 | Citations (PDF) |
| 52 | An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB) | 4.9 | 10 | Citations (PDF) |
| 53 | Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults | 2.6 | 44 | Citations (PDF) |
| 54 | Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group | 2.6 | 13 | Citations (PDF) |
| 55 | Benzodiazepines and antidepressants: Effects on cognitive and functional decline in Alzheimer's disease and Lewy body dementia | 2.4 | 34 | Citations (PDF) |
| 56 | Association of Malnutrition with Functional and Cognitive Trajectories in People Living with Dementia: A Five-Year Follow-Up Study | 2.7 | 39 | Citations (PDF) |
| 57 | Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European‐DLB consortium project | 0.7 | 7 | Citations (PDF) |
| 58 | Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture | 26.1 | 360 | Citations (PDF) |
| 59 | Resting-state EEG alpha/theta ratio related to neuropsychological test performance in Parkinson’s Disease | 0.9 | 38 | Citations (PDF) |
| 60 | Body mass index, performance on activities of daily living and cognition: analysis in two different populations | 3.3 | 22 | Citations (PDF) |
| 61 | Presynaptic accumulation of α-synuclein causes synaptopathy and progressive neurodegeneration in <i>Drosophila</i> | 3.8 | 19 | Citations (PDF) |
| 62 | Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease | 2.5 | 9 | Citations (PDF) |
| 63 | Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study | 6.8 | 54 | Citations (PDF) |
| 64 | A meta‐analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil | 2.4 | 38 | Citations (PDF) |
| 65 | Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores | 14.2 | 267 | Citations (PDF) |
| 66 | Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease | 8.4 | 62 | Citations (PDF) |
| 67 | A multicentre validation study of the diagnostic value of plasma neurofilament light | 14.2 | 429 | Citations (PDF) |
| 68 | Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies | 2.5 | 24 | Citations (PDF) |
| 69 | Parkinson disease-associated cognitive impairment | 26.2 | 1,005 | Citations (PDF) |
| 70 | A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer’s disease, and mild cognitive impairment using brain 18F-FDG PET | 5.4 | 64 | Citations (PDF) |
| 71 | Validity and Cultural Generalisability of a 5-Minute AI-Based, Computerised Cognitive Assessment in Mild Cognitive Impairment and Alzheimer's Dementia | 2.7 | 45 | Citations (PDF) |
| 72 | Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies | 2.7 | 41 | Citations (PDF) |
| 73 | Serum tyrosine is associated with better cognition in Lewy body dementia | 2.5 | 20 | Citations (PDF) |
| 74 | Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer’s disease with dementia | 1.0 | 36 | Citations (PDF) |
| 75 | Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts | 3.7 | 51 | Citations (PDF) |
| 76 | Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimer’s Disease | 2.7 | 8 | Citations (PDF) |
| 77 | A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease | 26.1 | 864 | Citations (PDF) |
| 78 | Polypharmacy is associated with functional decline in Alzheimer's disease and Lewy body dementia | 3.7 | 20 | Citations (PDF) |
| 79 | Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies | 3.3 | 32 | Citations (PDF) |
| 80 | A genome-wide association study of plasma phosphorylated tau181 | 3.3 | 11 | Citations (PDF) |
| 81 | Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia | 2.6 | 4 | Citations (PDF) |
| 82 | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease | 0.7 | 288 | Citations (PDF) |
| 83 | Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020 | 1.0 | 180 | Citations (PDF) |
| 84 | Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression | 3.7 | 28 | Citations (PDF) |
| 85 | Examination of cognitive performance and mild behavioral impairment domains of apathy, mood, impulse dyscontrol, social inappropriateness and psychosis in cognitively normal adults aged 50 and over | 0.7 | 0 | Citations (PDF) |
| 86 | The impact of the COVID‐19 pandemic on cognitive health | 0.7 | 1 | Citations (PDF) |
| 87 | Long‐term cognitive and motor decline across the spectrum of Lewy body disease | 0.7 | 0 | Citations (PDF) |
| 88 | Hypertension, brain training and cognition in the healthy adults aged over 50 years: An online longitudinal study | 0.7 | 0 | Citations (PDF) |
| 89 | Repeated concussions associated with worsened working memory, attention and processing speed, but preserved delayed memory: A PROTECT study | 0.7 | 0 | Citations (PDF) |
| 90 | A remote digital tool for diagnosis and monitoring of Alzheimer’s disease | 0.7 | 3 | Citations (PDF) |
| 91 | Self and informant‐rated mild behavioral impairment and genetic risk for AD: The respondent matters | 0.7 | 2 | Citations (PDF) |
| 92 | A randomised placebo‐controlled study on the effects of anthocyanins for maintaining cognitive functioning in individuals at increased risk for dementia | 0.7 | 0 | Citations (PDF) |
| 93 | Associations between amygdala volume and trajectories of neuropsychiatric symptoms in Alzheimer’s disease and dementia with Lewy Bodies | 0.7 | 0 | Citations (PDF) |
| 94 | Augmented reality to detect subtle alterations in the early stages of Alzheimer’s disease: Preliminary results of the RADAR‐AD study | 0.7 | 1 | Citations (PDF) |
| 95 | Gait characteristics in preclinical Alzheimer’s disease: Preliminary results of the RADAR‐AD study | 0.7 | 3 | Citations (PDF) |
| 96 | Mediating effect of mutuality on caregiver burden in Parkinson’s disease partners | 2.7 | 27 | Citations (PDF) |
| 97 | Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults | 1.0 | 88 | Citations (PDF) |
| 98 | CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies | 2.0 | 14 | Citations (PDF) |
| 99 | Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation | 1.0 | 59 | Citations (PDF) |
| 100 | The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study | 2.3 | 77 | Citations (PDF) |
| 101 | Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine | 1.8 | 18 | Citations (PDF) |
| 102 | Components of the choline oxidation pathway modify the association between the apolipoprotein ε4 gene variant and cognitive decline in patients with dementia | 2.5 | 4 | Citations (PDF) |
| 103 | Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer’s Disease | 2.7 | 16 | Citations (PDF) |
| 104 | Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies | 5.3 | 54 | Citations (PDF) |
| 105 | β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies | 1.2 | 110 | Citations (PDF) |
| 106 | Hippocampal Subfields and Decline in Activities of Daily Living in Alzheimer’s Disease and Dementia With Lewy Bodies | 3.0 | 5 | Citations (PDF) |
| 107 | Psychosis in Alzheimer’s Disease | 4.7 | 52 | Citations (PDF) |
| 108 | The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies | 3.5 | 38 | Citations (PDF) |
| 109 | Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration? | 6.8 | 12 | Citations (PDF) |
| 110 | Selecting Remote Measurement Technologies to Optimize Assessment of Function in Early Alzheimer's Disease: A Case Study | 2.7 | 23 | Citations (PDF) |
| 111 | Systems Biology Approaches to Understand the Host–Microbiome Interactions in Neurodegenerative Diseases | 3.0 | 62 | Citations (PDF) |
| 112 | Psychiatric and neuropsychiatric syndromes and COVID-19 | 5.0 | 5 | Citations (PDF) |
| 113 | Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline | 7.8 | 299 | Citations (PDF) |
| 114 | An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene | 3.3 | 76 | Citations (PDF) |
| 115 | Neuropsychiatric Symptoms and Functional Decline in Alzheimerʼs Disease and Lewy Body Dementia | 2.7 | 33 | Citations (PDF) |
| 116 | Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer’s disease | 13.1 | 55 | Citations (PDF) |
| 117 | Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial | 2.5 | 17 | Citations (PDF) |
| 118 | Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19 | 2.7 | 56 | Citations (PDF) |
| 119 | Drug repositioning and repurposing for Alzheimer disease | 27.5 | 171 | Citations (PDF) |
| 120 | Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer’s Disease | 2.7 | 18 | Citations (PDF) |
| 121 | Trajectories of depressive symptoms and associated patterns of cognitive decline | 3.7 | 74 | Citations (PDF) |
| 122 | A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey | 2.7 | 1 | Citations (PDF) |
| 123 | Cleaved Annexin A1 is elevated in neurodegenerative dementia and is associated with pathological burden of amyloid and inflammatory cytokines | 0.7 | 2 | Citations (PDF) |
| 124 | Linking electronic dementia care records to national inpatient data in dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes | 0.7 | 3 | Citations (PDF) |
| 125 | Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes | 0.7 | 0 | Citations (PDF) |
| 126 | Clinical factors associated with progression to dementia in people with late‐life depression: A cohort study of patients in secondary care | 0.7 | 2 | Citations (PDF) |
| 127 | Decreased JNK3 levels are associated with amyloid plaque and neurofibrillary tangles in dementia patients | 0.7 | 1 | Citations (PDF) |
| 128 | Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer’s disease in the absence of AT(N) classification as the reference standard | 0.7 | 1 | Citations (PDF) |
| 129 | Neuropsychiatric symptoms correlated with functional trajectories among people living with Alzheimer’s disease dementia and Lewy body dementia | 0.7 | 0 | Citations (PDF) |
| 130 | The ANeED study: Ambroxol in new and early dementia with Lewy bodies | 0.7 | 2 | Citations (PDF) |
| 131 | A systematic review on the physical and mental health risk factors of mild cognitive impairment and Alzheimer’s disease in military veterans | 0.7 | 0 | Citations (PDF) |
| 132 | Data‐assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium | 0.7 | 1 | Citations (PDF) |
| 133 | A prospective long‐term study of TDP‐43 pathology in Alzheimer’s disease aggression | 0.7 | 1 | Citations (PDF) |
| 134 | Neuropsychiatric symptoms and cognitive decline: Trait or state effects? | 0.7 | 0 | Citations (PDF) |
| 135 | Functional alterations in visual networks underlie differences in the phenomenology of visual hallucinations in Lewy body disease | 0.7 | 0 | Citations (PDF) |
| 136 | Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson’s and Lewy body diseases | 0.7 | 0 | Citations (PDF) |
| 137 | Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson’s and Lewy body diseases | 0.7 | 1 | Citations (PDF) |
| 138 | Plasma‐based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease | 0.7 | 0 | Citations (PDF) |
| 139 | Plasma p‐tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post‐mortem and improves the clinical characterisation of cognitive decline | 0.7 | 3 | Citations (PDF) |
| 140 | The reliability of a deep learning model in external memory clinic MRI data: A multi‐cohort study | 0.7 | 1 | Citations (PDF) |
| 141 | FLAME: A computerized neuropsychological composite for trials in early dementia | 2.6 | 28 | Citations (PDF) |
| 142 | Urinary metabolic phenotyping for Alzheimer’s disease | 3.7 | 43 | Citations (PDF) |
| 143 | The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study | 14.1 | 146 | Citations (PDF) |
| 144 | Mental health of people living with dementia in care homes during COVID-19 pandemic | 1.0 | 57 | Citations (PDF) |
| 145 | Clinical factors associated with progression to dementia in people with late-life depression: a cohort study of patients in secondary care | 2.0 | 17 | Citations (PDF) |
| 146 | Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study | 3.3 | 29 | Citations (PDF) |
| 147 | Temporal Relationship Between Depressive Symptoms and Cognition in Mid and Late Life: A Longitudinal Cohort Study | 2.5 | 27 | Citations (PDF) |
| 148 | Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer’s Disease | 2.8 | 7 | Citations (PDF) |
| 149 | Colombian consortium for the study of Lewy body dementia COL-DLB | 0.8 | 5 | Citations (PDF) |
| 150 | Risk of Hospitalization in Patients with Alzheimer’s Disease and Lewy Body Dementia: Time to and Length of Stay | 2.7 | 8 | Citations (PDF) |
| 151 | An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders | 27.5 | 161 | Citations (PDF) |
| 152 | Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease | 3.9 | 75 | Citations (PDF) |
| 153 | Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis | 3.5 | 21 | Citations (PDF) |
| 154 | Association between physical activity and cognition in Mexican and Korean older adults | 3.7 | 13 | Citations (PDF) |
| 155 | Research criteria for the diagnosis of prodromal dementia with Lewy bodies | 1.2 | 652 | Citations (PDF) |
| 156 | Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes | 5.4 | 38 | Citations (PDF) |
| 157 | The Mental and Physical Health of Older Adults With a Genetic Predisposition for Autism | 5.1 | 11 | Citations (PDF) |
| 158 | Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer’s Disease | 8.9 | 182 | Citations (PDF) |
| 159 | Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer’s Disease | 2.7 | 7 | Citations (PDF) |
| 160 | Asociación entre pérdida del apetito y niveles de albúmina en adultos mayores con enfermedad de Alzheimer leve | 0.5 | 1 | Citations (PDF) |
| 161 | Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer’s pathology and progression to dementia. | 2.7 | 15 | Citations (PDF) |
| 162 | Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration | 4.8 | 64 | Citations (PDF) |
| 163 | Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer’s disease | 2.0 | 29 | Citations (PDF) |
| 164 | Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia – A Pilot Study | 2.4 | 19 | Citations (PDF) |
| 165 | Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer’s disease | 5.8 | 45 | Citations (PDF) |
| 166 | Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia | 3.8 | 21 | Citations (PDF) |
| 167 | Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration | 5.1 | 146 | Citations (PDF) |
| 168 | European Dlb Consortium: Diagnostic and Prognostic Biomarkers in Dementia With Lewy Bodies, a Multicenter International Initiative | 3.0 | 29 | Citations (PDF) |
| 169 | Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults | 1.0 | 195 | Citations (PDF) |
| 170 | Prevalence of late-life depression and gap in mental health service use across European regions | 0.3 | 133 | Citations (PDF) |
| 171 | GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study | 3.7 | 68 | Citations (PDF) |
| 172 | Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression | 7.5 | 58 | Citations (PDF) |
| 173 | The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress | 2.4 | 17 | Citations (PDF) |
| 174 | Combinatory microRNA serum signatures as classifiers of Parkinson's disease | 1.8 | 34 | Citations (PDF) |
| 175 | Association of depressive symptoms and subjective memory complaints with the incidence of cognitive impairment in older adults with high blood pressure | 2.8 | 21 | Citations (PDF) |
| 176 | Glial activation and inflammation along the Alzheimer’s disease continuum | 9.2 | 240 | Citations (PDF) |
| 177 | Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia | 2.7 | 8 | Citations (PDF) |
| 178 | Metabolic patterns across core features in dementia with lewy bodies | 6.5 | 61 | Citations (PDF) |
| 179 | Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways | 6.8 | 25 | Citations (PDF) |
| 180 | A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease | 11.5 | 73 | Citations (PDF) |
| 181 | Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort | 3.6 | 47 | Citations (PDF) |
| 182 | Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies | 2.7 | 21 | Citations (PDF) |
| 183 | The relationship between the frequency of number‐puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over | 2.4 | 15 | Citations (PDF) |
| 184 | Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer’s disease and neocortical Lewy body disease | 3.7 | 16 | Citations (PDF) |
| 185 | Commentary: A posterior-to-anterior shift of brain functional dynamics in aging | 4.1 | 4 | Citations (PDF) |
| 186 | The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein ε4 Allele Variant in Patients With Dementia | 3.8 | 3 | Citations (PDF) |
| 187 | The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia With Lewy Bodies and Alzheimer's Disease | 2.5 | 32 | Citations (PDF) |
| 188 | A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium | 0.7 | 79 | Citations (PDF) |
| 189 | Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: A meta-analysis of longitudinal studies | 12.1 | 108 | Citations (PDF) |
| 190 | Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk | 26.1 | 2,171 | Citations (PDF) |
| 191 | The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS) | 2.5 | 61 | Citations (PDF) |
| 192 | In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion | 2.7 | 6 | Citations (PDF) |
| 193 | Investigating the relationship between age of onset of depressive disorder and cognitive function | 2.4 | 29 | Citations (PDF) |
| 194 | Reduced Walking Speed in Subjective and Mild Cognitive Impairment: A Cross-Sectional Study | 1.0 | 41 | Citations (PDF) |
| 195 | Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer’s and Lewy Body Diseases | 2.7 | 66 | Citations (PDF) |
| 196 | Risk factors for non-motor symptoms in Parkinson's disease | 12.9 | 305 | Citations (PDF) |
| 197 | Patterns of carer distress over time in mild dementia | 2.4 | 16 | Citations (PDF) |
| 198 | Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment | 5.3 | 19 | Citations (PDF) |
| 199 | Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials | 5.3 | 22 | Citations (PDF) |
| 200 | Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications | 2.6 | 56 | Citations (PDF) |
| 201 | Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study | 3.3 | 79 | Citations (PDF) |
| 202 | Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approachBrain, 2018, 141, 582-595 | 8.9 | 204 | Citations (PDF) |
| 203 | Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease | 0.7 | 80 | Citations (PDF) |
| 204 | Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta‐analyses | 1.8 | 63 | Citations (PDF) |
| 205 | Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia | 1.0 | 38 | Citations (PDF) |
| 206 | Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia | 11.3 | 145 | Citations (PDF) |
| 207 | P3‐243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY | 0.7 | 0 | Citations (PDF) |
| 208 | P3‐554: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATION‐BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY | 0.7 | 2 | Citations (PDF) |
| 209 | P1‐523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBI‐C) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS | 0.7 | 0 | Citations (PDF) |
| 210 | P1‐151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE | 0.7 | 0 | Citations (PDF) |
| 211 | P2‐483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER | 0.7 | 0 | Citations (PDF) |
| 212 | P1‐658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS | 0.7 | 1 | Citations (PDF) |
| 213 | O1‐10‐04: ABNORMALITIES OF RESTING STATE FUNCTIONAL CORTICAL CONNECTIVITY IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S AND LEWY BODY DISEASES: AN EEG STUDY | 0.7 | 0 | Citations (PDF) |
| 214 | Meta-analysis of Alzheimer’s disease on 9,751 samples from Norway and IGAP study identifies four risk loci | 3.7 | 59 | Citations (PDF) |
| 215 | Cognitive Interventions in Parkinson’s Disease: Where We Want to Go within 20 Years | 3.7 | 27 | Citations (PDF) |
| 216 | Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease | 4.9 | 25 | Citations (PDF) |
| 217 | Mediating Effect of Mutuality on Health-Related Quality of Life in Patients with Parkinson’s Disease | 1.0 | 7 | Citations (PDF) |
| 218 | P3‐001: A RANDOMIZED, PLACEBO‐CONTROLLED TRIAL TO INVESTIGATE SAFETY OF BUPRENORPHINE TRANSDERMAL SYSTEM FOR PAIN MANAGEMENT IN PEOPLE WITH DEMENTIA | 0.7 | 0 | Citations (PDF) |
| 219 | Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM) | 3.2 | 39 | Citations (PDF) |
| 220 | A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimer’s Disease | 2.5 | 20 | Citations (PDF) |
| 221 | Course of neuropsychiatric symptoms in dementia: 5‐year longitudinal study | 2.4 | 89 | Citations (PDF) |
| 222 | Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease | 6.8 | 63 | Citations (PDF) |
| 223 | Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer’s Disease: A Longitudinal Study | 2.7 | 10 | Citations (PDF) |
| 224 | Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM) | 3.5 | 25 | Citations (PDF) |
| 225 | Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies | 6.8 | 37 | Citations (PDF) |
| 226 | Cognition among individuals along a spectrum of increased risk for Parkinson’s disease | 2.5 | 36 | Citations (PDF) |
| 227 | Amyloid-β and Parkinson’s disease | 3.5 | 116 | Citations (PDF) |
| 228 | (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer’s Disease | 1.5 | 18 | Citations (PDF) |
| 229 | Potentially inappropriate medications and drug–drug interactions in home‐dwelling people with mild dementia | 2.4 | 28 | Citations (PDF) |
| 230 | The psychosis spectrum in Parkinson disease | 27.5 | 329 | Citations (PDF) |
| 231 | Effect of Vascular Risk Factors on the Progression of Mild Alzheimer’s Disease and Lewy Body Dementia | 2.7 | 22 | Citations (PDF) |
| 232 | SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics | 3.7 | 27 | Citations (PDF) |
| 233 | Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia | 2.7 | 17 | Citations (PDF) |
| 234 | Cognitive decline in Parkinson disease | 27.5 | 910 | Citations (PDF) |
| 235 | Lewy Body Dementias | 1.3 | 3 | Citations (PDF) |
| 236 | Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study | 3.3 | 97 | Citations (PDF) |
| 237 | Associations between pain and depression in nursing home patients at different stages of dementia | 4.8 | 48 | Citations (PDF) |
| 238 | A new tool to identify patients with Parkinson's disease at increased risk of dementia | 12.9 | 7 | Citations (PDF) |
| 239 | Psychosis in Parkinson's Disease | 1.1 | 38 | Citations (PDF) |
| 240 | Diagnosis and management of dementia with Lewy bodies | 1.2 | 3,819 | Citations (PDF) |
| 241 | Novel evidence associates higher plasma α-synuclein levels and cognitive impairment in Parkinson’s disease | 2.0 | 12 | Citations (PDF) |
| 242 | Effects of Risperidone and Galantamine Treatment on Alzheimer’s Disease Biomarker Levels in Cerebrospinal Fluid | 2.7 | 12 | Citations (PDF) |
| 243 | Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort | 2.7 | 79 | Citations (PDF) |
| 244 | The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review | 2.4 | 115 | Citations (PDF) |
| 245 | Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative | 2.0 | 95 | Citations (PDF) |
| 246 | The prognosis of dementia with Lewy bodies | 12.9 | 193 | Citations (PDF) |
| 247 | Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer’s Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load | 2.7 | 28 | Citations (PDF) |
| 248 | Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer’s and Parkinson’s Diseases: An EEG Study | 2.7 | 56 | Citations (PDF) |
| 249 | [P3–017]: HEADWAY‐DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT‐101) IN DEMENTIA WITH LEWY BODIES | 0.7 | 4 | Citations (PDF) |
| 250 | Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations | 4.5 | 20 | Citations (PDF) |
| 251 | Impaired synaptic function is linked to cognition in Parkinson's disease | 3.9 | 30 | Citations (PDF) |
| 252 | Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease | 1.1 | 36 | Citations (PDF) |
| 253 | Synaptic proteins in CSF relate to Parkinson’s disease stage markers | 7.5 | 68 | Citations (PDF) |
| 254 | Classifying Alzheimer's disease, Lewy body dementia, and normal controls using 3D texture analysis in magnetic resonance images | 6.4 | 19 | Citations (PDF) |
| 255 | [P1–235]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUB‐UNITS IN ALZHEIMER's DISEASE AND LEWY BODY DEMENTIAS | 0.7 | 0 | Citations (PDF) |
| 256 | [P3–243]: A MASS SPECTROMETRY‐BASED DISCOVERY AND REPLICATION OF A MULTI‐ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY | 0.7 | 0 | Citations (PDF) |
| 257 | [P4–154]: DETECTING AT‐RISK CASES FOR ALZHEIMER's DISEASE | 0.7 | 0 | Citations (PDF) |
| 258 | [P1–299]: AN EVALUATION OF PREDICTORS AND COGNITIVE DECLINE ASSOCIATED WITH PERSISTENT AND TRANSIENT PSYCHOTIC SYMPTOMS IN ALZHEIMER's DISEASE | 0.7 | 1 | Citations (PDF) |
| 259 | [P1–456]: INCREASED PSER129 α‐SYNUCLEIN IS ASSOCIATED WITH SYNAPTIC DEFICITS IN DEMENTIA WITH LEWY BODIES | 0.7 | 0 | Citations (PDF) |
| 260 | [P1–564]: RISK AND DURATION OF HOSPITALIZATION IN DEMENTIA WITH LEWY BODIES | 0.7 | 1 | Citations (PDF) |
| 261 | [P2–204]: RPT6, 20S α‐6 AND α‐3 PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH COGNITIVE DECLINE IN ALZHEIMER's DISEASE AND LEWY BODY DEMENTIAS | 0.7 | 0 | Citations (PDF) |
| 262 | [F5–01–03]: CLINICO‐PATHOLOGIC ASSOCIATIONS IN DLB: RELEVANCE FOR DIAGNOSIS AND TREATMENT | 0.7 | 0 | Citations (PDF) |
| 263 | Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology | 2.7 | 83 | Citations (PDF) |
| 264 | Screening for Alzheimer’s Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients | 2.7 | 9 | Citations (PDF) |
| 265 | New Therapeutic Strategies for Lewy Body Dementias | 4.7 | 31 | Citations (PDF) |
| 266 | MRI-Based Classification Models in Prediction of Mild Cognitive Impairment and Dementia in Late-Life Depression | 4.1 | 79 | Citations (PDF) |
| 267 | REM Sleep Behavior Disorder Is Not Associated with a More Rapid Cognitive Decline in Mild Dementia | 2.5 | 9 | Citations (PDF) |
| 268 | Determinants of Dyadic Relationship and Its Psychosocial Impact in Patients with Parkinson’s Disease and Their Spouses | 1.0 | 19 | Citations (PDF) |
| 269 | Detecting At-Risk Alzheimer’s Disease Cases | 2.7 | 64 | Citations (PDF) |
| 270 | Antibodies to Signaling Molecules and Receptors in Alzheimer’s Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function | 2.7 | 15 | Citations (PDF) |
| 271 | Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease | 2.5 | 134 | Citations (PDF) |
| 272 | The Lewy Body Dementias: Dementia with Lewy Bodies and Related Syndromes 2017, , 211-224 | | 0 | Citations (PDF) |
| 273 | Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia | 2.7 | 30 | Citations (PDF) |
| 274 | Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer’s and Parkinson’s Diseases | 3.7 | 12 | Citations (PDF) |
| 275 | Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia | 5.3 | 99 | Citations (PDF) |
| 276 | Unfolded protein response is activated in <scp>L</scp>ewy body dementias | 3.3 | 50 | Citations (PDF) |
| 277 | Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson’s Disease Dementia | 3.7 | 6 | Citations (PDF) |
| 278 | Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study | 2.0 | 68 | Citations (PDF) |
| 279 | Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer’s Disease | 2.7 | 15 | Citations (PDF) |
| 280 | EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study | 2.7 | 61 | Citations (PDF) |
| 281 | O3‐04‐02: Clinico‐Pathologic Correlations in Dementia with Lewy Bodies (DLB): A Prospective Cohort Study | 0.7 | 0 | Citations (PDF) |
| 282 | Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer’s Disease are Associated with Parkinsonism | 2.7 | 22 | Citations (PDF) |
| 283 | Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia | 0.7 | 151 | Citations (PDF) |
| 284 | Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients | 2.5 | 14 | Citations (PDF) |
| 285 | Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias | 3.2 | 28 | Citations (PDF) |
| 286 | Non-Alzheimer Dementias | 2.8 | 0 | Citations (PDF) |
| 287 | Signs of Imminent Dying and Change in Symptom Intensity During Pharmacological Treatment in Dying Nursing Home Patients: A Prospective Trajectory Study | 2.5 | 28 | Citations (PDF) |
| 288 | Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways | 4.2 | 36 | Citations (PDF) |
| 289 | Loss of <scp>D</scp>opamine <scp>T</scp>ransporter <scp>B</scp>inding and <scp>C</scp>linical <scp>S</scp>ymptoms in <scp>D</scp>ementia <scp>W</scp>ith <scp>L</scp>ewy <scp>B</scp>odies | 5.3 | 35 | Citations (PDF) |
| 290 | Evolution of clinical features in possible DLB depending on FP-CIT SPECT result | 1.2 | 17 | Citations (PDF) |
| 291 | Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort | 2.7 | 104 | Citations (PDF) |
| 292 | Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease: a cross-sectional study | 7.5 | 30 | Citations (PDF) |
| 293 | Association of Platelet Serotonin Levels in Alzheimer’s Disease with Clinical and Cerebrospinal Fluid Markers | 2.7 | 27 | Citations (PDF) |
| 294 | Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer’s Disease | 2.7 | 12 | Citations (PDF) |
| 295 | Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer's disease | 2.4 | 139 | Citations (PDF) |
| 296 | CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia | 3.3 | 37 | Citations (PDF) |
| 297 | A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease | 6.8 | 52 | Citations (PDF) |
| 298 | Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 2011: trend analyses of four data samples | 1.8 | 61 | Citations (PDF) |
| 299 | Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders | 4.0 | 65 | Citations (PDF) |
| 300 | MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study | 3.6 | 126 | Citations (PDF) |
| 301 | Corrigendum to ‘Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 2011: trend analyses of four data samples’ | 1.8 | 2 | Citations (PDF) |
| 302 | Cognitive impairment in Parkinson's disease and dementia with Lewy bodies | 1.8 | 127 | Citations (PDF) |
| 303 | Isoelectric point region pI≈7.4 as a treasure island of abnormal proteoforms in blood | 2.2 | 8 | Citations (PDF) |
| 304 | P2-135: CSF aß42 is related to cortical metabolism (FDG-PET) in non-demented parkinson's disease patients 2015, 11, P536-P537 | | 0 | Citations (PDF) |
| 305 | Neuropsychiatric Symptoms in Parkinson’s Disease | 3.7 | 85 | Citations (PDF) |
| 306 | Harnessing the power of cohort studies for dementia research | 1.2 | 7 | Citations (PDF) |
| 307 | Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson’s Disease | 3.7 | 42 | Citations (PDF) |
| 308 | Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s Disease | 2.7 | 28 | Citations (PDF) |
| 309 | Reply to letter to the editor ‘Independent application of MoCA/MMSE conversion’ by Armstrong et al. | 5.3 | 0 | Citations (PDF) |
| 310 | Personality Changes after Deep Brain Stimulation in Parkinson’s Disease | 1.0 | 47 | Citations (PDF) |
| 311 | Classifying Dementia Using Local Binary Patterns from Different Regions in Magnetic Resonance Images | 1.3 | 33 | Citations (PDF) |
| 312 | COSMOS—improving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial | 10.9 | 50 | Citations (PDF) |
| 313 | O5‐03‐04: Clinical characteristics and course of dlb: Results from a large longitudinal multicentre cohort | 0.7 | 2 | Citations (PDF) |
| 314 | A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD) | 2.5 | 28 | Citations (PDF) |
| 315 | Medial Temporal Lobe Atrophy and Depressive Symptoms in Elderly Patients With and Without Alzheimer Disease | 2.8 | 24 | Citations (PDF) |
| 316 | 5-HT1B and other related serotonergic proteins are altered in APPswe mutation | 2.0 | 18 | Citations (PDF) |
| 317 | Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease | 1.8 | 72 | Citations (PDF) |
| 318 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia | 7.3 | 1,452 | Citations (PDF) |
| 319 | Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease | 26.1 | 316 | Citations (PDF) |
| 320 | Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease | 3.8 | 108 | Citations (PDF) |
| 321 | Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease | 5.3 | 294 | Citations (PDF) |
| 322 | Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease | 10.1 | 156 | Citations (PDF) |
| 323 | Lewy body dementias | 14.8 | 529 | Citations (PDF) |
| 324 | Neuroanatomical correlates of late-life depression and associated cognitive changes | 3.3 | 36 | Citations (PDF) |
| 325 | Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies | 2.4 | 86 | Citations (PDF) |
| 326 | Depression and Synaptic Zinc Regulation in Alzheimer Disease, Dementia with Lewy Bodies, and Parkinson Disease Dementia | 1.0 | 45 | Citations (PDF) |
| 327 | Regional Multiple Pathology Scores Are Associated with Cognitive Decline in <scp>L</scp>ewy Body Dementias | 4.8 | 173 | Citations (PDF) |
| 328 | Grey Matter Changes in Cognitively Impaired Parkinson's Disease Patients | 2.5 | 74 | Citations (PDF) |
| 329 | Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits | 3.4 | 97 | Citations (PDF) |
| 330 | Neuropsychiatric symptoms in dementia—A role for neuroinflammation? | 3.6 | 54 | Citations (PDF) |
| 331 | The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review | 1.0 | 146 | Citations (PDF) |
| 332 | Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study | 2.0 | 54 | Citations (PDF) |
| 333 | A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease | 6.8 | 23 | Citations (PDF) |
| 334 | Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness | 3.5 | 272 | Citations (PDF) |
| 335 | Apolipoprotein E 2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort | 2.0 | 71 | Citations (PDF) |
| 336 | White matter integrity and cognition in Parkinson's disease: a cross-sectional study | 2.0 | 47 | Citations (PDF) |
| 337 | Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment | 3.3 | 116 | Citations (PDF) |
| 338 | Cognitive executive impairment and dopaminergic deficits in <i>de novo</i> Parkinson's disease | 5.3 | 80 | Citations (PDF) |
| 339 | Comorbidity profile in dementia with Lewy bodies versus Alzheimer’s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry | 6.8 | 37 | Citations (PDF) |
| 340 | Conversion between Mini‐Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale‐2 scores in Parkinson's disease | 5.3 | 109 | Citations (PDF) |
| 341 | Short- and Long-term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study | 1.0 | 70 | Citations (PDF) |
| 342 | Psychiatric issues in cognitive impairment | 5.3 | 45 | Citations (PDF) |
| 343 | Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia | 2.4 | 84 | Citations (PDF) |
| 344 | Cortical Changes Associated with Depression and Antidepressant Use in Alzheimer and Lewy Body Dementia: An MRI Surface-based Morphometric Study | 1.0 | 47 | Citations (PDF) |
| 345 | Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease | 2.0 | 61 | Citations (PDF) |
| 346 | The importance of pain management in older people with dementia | 5.3 | 86 | Citations (PDF) |
| 347 | Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias | 1.0 | 24 | Citations (PDF) |
| 348 | The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? | 0.7 | 274 | Citations (PDF) |
| 349 | The Use and Costs of Formal Care in Newly Diagnosed Dementia: A Three-Year Prospective Follow-Up Study | 1.0 | 57 | Citations (PDF) |
| 350 | Initial cognitive decline is associated with cortical thinning in early Parkinson disease | 1.2 | 187 | Citations (PDF) |
| 351 | The Response of Agitated Behavior to Pain Management in Persons with Dementia | 1.0 | 148 | Citations (PDF) |
| 352 | A 5‐YEAR LONGITUDINAL STUDY OF PATIENTS WITH DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE | 0.7 | 1 | Citations (PDF) |
| 353 | The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review – CORRIGENDUM | 1.0 | 4 | Citations (PDF) |
| 354 | Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases | 27.5 | 161 | Citations (PDF) |
| 355 | A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer¿s disease | 6.8 | 22 | Citations (PDF) |
| 356 | Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia | 0.6 | 22 | Citations (PDF) |
| 357 | O3-10-01: Clinical course of Lewy-body disease: Cognitive decline and mortality 2013, 9, P537-P538 | | 1 | Citations (PDF) |
| 358 | Many roads lead to Parkinson's disease | 5.3 | 3 | Citations (PDF) |
| 359 | Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management | 3.5 | 59 | Citations (PDF) |
| 360 | Using biomarkers to disentangle different causes of Parkinsonism | 2.0 | 1 | Citations (PDF) |
| 361 | (<sup>123</sup>I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study | 2.0 | 27 | Citations (PDF) |
| 362 | Cerebrospinal fluid amyloid- and phenotypic heterogeneity in de novo Parkinson's disease | 2.0 | 61 | Citations (PDF) |
| 363 | Overview of Parkinson's disease: epidemiology, diagnosis, course, medical and surgical management 2013, , 1-13 | | 0 | Citations (PDF) |
| 364 | Parkinson’s disease: pathology, anatomy, and behavior 2013, , 14-24 | | 0 | Citations (PDF) |
| 365 | The boundaries of Parkinson’s disease dementia and dementia with Lewy bodies 2013, , 40-52 | | 0 | Citations (PDF) |
| 366 | Cognitive assessment in Parkinson’s disease 2013, , 53-64 | | 0 | Citations (PDF) |
| 367 | Clinical assessment: mood and motivation 2013, , 65-72 | | 0 | Citations (PDF) |
| 368 | Imaging and behavior in Parkinson’s disease: structural imaging 2013, , 73-88 | | 0 | Citations (PDF) |
| 369 | Imaging and behavior in Parkinson’s disease: functional imaging 2013, , 89-96 | | 0 | Citations (PDF) |
| 370 | Diagnosis and biomarkers: CSF 2013, , 97-108 | | 0 | Citations (PDF) |
| 371 | Depression 2013, , 109-118 | | 0 | Citations (PDF) |
| 372 | Anxiety 2013, , 119-130 | | 0 | Citations (PDF) |
| 373 | Apathy 2013, , 131-139 | | 0 | Citations (PDF) |
| 374 | Impulse control disorders and related behaviors 2013, , 140-152 | | 3 | Citations (PDF) |
| 375 | Psychosis 2013, , 153-162 | | 0 | Citations (PDF) |
| 376 | Early cognitive impairment 2013, , 163-176 | | 1 | Citations (PDF) |
| 377 | Parkinson’s disease dementia 2013, , 177-191 | | 0 | Citations (PDF) |
| 378 | Sleep disturbances 2013, , 192-210 | | 0 | Citations (PDF) |
| 379 | Drug treatment and behavior 2013, , 211-229 | | 0 | Citations (PDF) |
| 380 | Surgical treatment and behavior 2013, , 230-243 | | 0 | Citations (PDF) |
| 381 | Clinical trials for psychotropic agents in Parkinson's disease using psychosis as a model 2013, , 244-254 | | 0 | Citations (PDF) |
| 382 | The impact of neuropsychiatric symptoms on quality of life in Parkinson's disease 2013, , 255-260 | | 0 | Citations (PDF) |
| 383 | Neuropsychiatric and cognitive disorders in other parkinsonian disorders 2013, , 261-274 | | 4 | Citations (PDF) |
| 384 | Neuropsychiatric aspects of the on/off phenomenon 2013, , 275-284 | | 1 | Citations (PDF) |
| 385 | Treatment of neuropsychiatric disturbances in Parkinson's disease: future prospects and strategies 2013, , 285-291 | | 0 | Citations (PDF) |
| 386 | The genetics of behavior and cognition in Parkinson’s disease 2013, , 25-39 | | 0 | Citations (PDF) |
| 387 | Mapping Cortical Atrophy in Parkinson's Disease Patients with Dementia | 3.7 | 39 | Citations (PDF) |
| 388 | Journal Watch: Our Panel of Experts Highlight the Most Important Research Articles Across the Spectrum of Topics Relevant to the Field of Neurodegenerative Disease Management | 3.0 | 0 | Citations (PDF) |
| 389 | Diffusion Tensor Imaging Surpasses Cerebrospinal Fluid as Predictor of Cognitive Decline and Medial Temporal Lobe Atrophy in Subjective Cognitive Impairment and Mild Cognitive Impairment | 2.7 | 101 | Citations (PDF) |
| 390 | Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson&#39;s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem) | 2.5 | 36 | Citations (PDF) |
| 391 | Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias | 3.6 | 3 | Citations (PDF) |
| 392 | Management of Parkinson???s Disease Dementia | 3.5 | 13 | Citations (PDF) |
| 393 | Rivastigmine in Parkinson??s Disease Dementia | 6.8 | 1 | Citations (PDF) |
| 394 | Biomarkers for dementia diagnosis: differentiating DLB and FTD may be difficult | 2.0 | 1 | Citations (PDF) |
| 395 | The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia | 1.0 | 47 | Citations (PDF) |
| 396 | Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial | 14.8 | 156 | Citations (PDF) |
| 397 | Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment | 12.9 | 477 | Citations (PDF) |
| 398 | Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease | 3.5 | 262 | Citations (PDF) |
| 399 | No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias | 2.0 | 7 | Citations (PDF) |
| 400 | Assessment and treatment of pain in people with dementia | 27.5 | 302 | Citations (PDF) |
| 401 | Multispectral MRI segmentation of age related white matter changes using a cascade of support vector machines | 0.8 | 45 | Citations (PDF) |
| 402 | The Impact of Autonomic Dysfunction on Survival in Patients with Dementia with Lewy Bodies and Parkinson's Disease with Dementia | 2.5 | 126 | Citations (PDF) |
| 403 | Relationship between Orthostatic Hypotension and White Matter Hyperintensity Load in Older Patients with Mild Dementia | 2.5 | 14 | Citations (PDF) |
| 404 | Clinical Trials of Dementia With Lewy Bodies and Parkinson’s Disease Dementia | 4.7 | 41 | Citations (PDF) |
| 405 | Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease | 5.3 | 529 | Citations (PDF) |
| 406 | Systematic review of services providing information and/or advice to people with dementia and/or their caregivers | 2.4 | 76 | Citations (PDF) |
| 407 | Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines | 5.3 | 2,341 | Citations (PDF) |
| 408 | Multivariate classification of patients with Alzheimer’s and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study | 3.5 | 50 | Citations (PDF) |
| 409 | Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial | 2.5 | 214 | Citations (PDF) |
| 410 | Parkinson's disease dementia and dementia with Lewy bodies – epidemiology, risk factors and biomarkers | 0.2 | 2 | Citations (PDF) |
| 411 | Developing predictive biomarkers for dementia of Parkinson’s disease | 3.3 | 0 | Citations (PDF) |
| 412 | Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial | 0.1 | 496 | Citations (PDF) |
| 413 | A Novel Blood Test for the Early Detection of Alzheimer's Disease | 2.7 | 74 | Citations (PDF) |
| 414 | Cognitive and Psychiatric Disturbances in Parkinson’s Disease | 0.4 | 6 | Citations (PDF) |
| 415 | Dementia associated with Parkinson’s disease: Applying the Movement Disorder Society Task Force criteria | 1.8 | 65 | Citations (PDF) |
| 416 | Executive Dysfunction in Mild Cognitive Impairment is Associated with Changes in Frontal and Cingulate White Matter Tracts | 2.7 | 62 | Citations (PDF) |
| 417 | Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data | 5.1 | 69 | Citations (PDF) |
| 418 | Alzheimer's disease | 14.8 | 2,292 | Citations (PDF) |
| 419 | Man with fluctuating confusion 2011, , 148-154 | | 0 | Citations (PDF) |
| 420 | Nonmotor Symptoms of Parkinson's Disease | 1.0 | 1 | Citations (PDF) |
| 421 | Authors' reply to McShane and Regnard | 0.1 | 0 | Citations (PDF) |
| 422 | Our Panel of Experts Highlight the Most Important Research Articles Across the Spectrum of Topics Relevant to the Field of Neurodegenerative Disease Management | 3.0 | 0 | Citations (PDF) |
| 423 | Mania After Administration of Cholinesterase Inhibitors in Patients With Dementia and Comorbid Bipolar Disorder | 2.0 | 13 | Citations (PDF) |
| 424 | Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. | 2.7 | 95 | Citations (PDF) |
| 425 | Depression in dementia | 4.9 | 292 | Citations (PDF) |
| 426 | Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method | 3.5 | 108 | Citations (PDF) |
| 427 | Mild Cognitive Impairment in Parkinson’s Disease | 4.7 | 139 | Citations (PDF) |
| 428 | Nonlinear decline of mini-mental state examination in Parkinson's disease | 5.3 | 43 | Citations (PDF) |
| 429 | Ventricular enlargement and mild cognitive impairment in early Parkinson's disease | 5.3 | 62 | Citations (PDF) |
| 430 | Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease | 5.3 | 33 | Citations (PDF) |
| 431 | The economic impact of cognitive impairment in Parkinson's disease | 5.3 | 121 | Citations (PDF) |
| 432 | Cognitive impairment in nondemented Parkinson's disease | 5.3 | 120 | Citations (PDF) |
| 433 | Hypertension is a potential risk factor for vascular dementia: systematic review | 2.4 | 204 | Citations (PDF) |
| 434 | Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features | 2.4 | 39 | Citations (PDF) |
| 435 | The role of pain treatment in managing the behavioural and psychological symptoms of dementia (BPSD) | 0.8 | 37 | Citations (PDF) |
| 436 | CSF amyloid 38 as a novel diagnostic marker for dementia with Lewy bodies | 2.0 | 52 | Citations (PDF) |
| 437 | Depression in Parkinson disease—epidemiology, mechanisms and management | 27.5 | 527 | Citations (PDF) |
| 438 | Biomarkører i spinalvæske ved demens | 0.1 | 5 | Citations (PDF) |
| 439 | Nye diagnosekriterier for Alzheimers sykdom | 0.1 | 0 | Citations (PDF) |
| 440 | Effects of Rivastigmine in Alzheimer's Disease Patients with and Without Hallucinations | 2.7 | 20 | Citations (PDF) |
| 441 | Rivastigmine for the Treatment of Parkinson’s Disease Dementia | 0.4 | 0 | Citations (PDF) |
| 442 | Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study | 3.3 | 60 | Citations (PDF) |
| 443 | The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia | 2.4 | 81 | Citations (PDF) |
| 444 | Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia | 5.3 | 155 | Citations (PDF) |
| 445 | Gray matter correlations of cognition in incident Parkinson's disease | 5.3 | 62 | Citations (PDF) |
| 446 | Frequency and Correlates of Caregiver‐Reported Sleep Disturbances in a Sample of Persons with Early Dementia | 2.7 | 130 | Citations (PDF) |
| 447 | The Epidemiology of Dementia Associated with Parkinson's Disease | 4.8 | 300 | Citations (PDF) |
| 448 | Evaluating Rivastigmine in Mild-to-Moderate Parkinson’s Disease Dementia Using ADAS-Cog Items | 2.2 | 23 | Citations (PDF) |
| 449 | CSF amyloid- and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study | 2.0 | 210 | Citations (PDF) |
| 450 | A 12-Year Population-Based Study of Psychosis in Parkinson Disease | 5.2 | 357 | Citations (PDF) |
| 451 | Is physical activity a potential preventive factor for vascular dementia? A systematic review | 2.7 | 181 | Citations (PDF) |
| 452 | α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies | 1.0 | 21 | Citations (PDF) |
| 453 | Biomarkers of PD progression | 1.2 | 4 | Citations (PDF) |
| 454 | The epidemiology of dementia associated with Parkinson disease | 0.8 | 434 | Citations (PDF) |
| 455 | Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study | 2.0 | 218 | Citations (PDF) |
| 456 | The Effect of Staff Training on Agitation and Use of Restraint in Nursing Home Residents With Dementia | 2.9 | 75 | Citations (PDF) |
| 457 | Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity | 1.0 | 64 | Citations (PDF) |
| 458 | APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study | 2.8 | 55 | Citations (PDF) |
| 459 | Person-centred care and care mapping in dementia | 12.9 | 12 | Citations (PDF) |
| 460 | Neuropsychiatric symptoms in Parkinson's disease | 5.3 | 513 | Citations (PDF) |
| 461 | Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial | 12.9 | 440 | Citations (PDF) |
| 462 | Prevalence and clinical correlates of apathy in Parkinson's disease: A community-based study | 1.8 | 163 | Citations (PDF) |
| 463 | The association between motor subtypes and psychopathology in Parkinson's disease | 1.8 | 192 | Citations (PDF) |
| 464 | Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF | 7.5 | 196 | Citations (PDF) |
| 465 | White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease | 4.8 | 68 | Citations (PDF) |
| 466 | CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment | 7.3 | 1,051 | Citations (PDF) |
| 467 | Pain and Its Relationship to Depression in Parkinson Disease | 1.0 | 85 | Citations (PDF) |
| 468 | Parkinson Disease With Dementia | 1.5 | 197 | Citations (PDF) |
| 469 | Apathy in drug-naïve patients with incident Parkinson’s disease: the Norwegian ParkWest study | 3.5 | 91 | Citations (PDF) |
| 470 | Kognitiv svikt ved terminal nyresykdom | 0.1 | 4 | Citations (PDF) |
| 471 | Pharmacological management of neuropsychiatric symptoms in people with dementia 2009, , 105-116 | | 0 | Citations (PDF) |
| 472 | A systematic review of prevalence studies of depression in Parkinson's disease | 5.3 | 1,098 | Citations (PDF) |
| 473 | Scales to assess psychosis in Parkinson's disease: Critique and recommendations | 5.3 | 194 | Citations (PDF) |
| 474 | Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study––The Bergen District Nursing Home Study (BEDNURS) | 2.4 | 79 | Citations (PDF) |
| 475 | Validation of the Unified Parkinson's Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease | 1.8 | 36 | Citations (PDF) |
| 476 | Grey matter atrophy in early versus late dementia in Parkinson's disease | 1.8 | 19 | Citations (PDF) |
| 477 | Who Suffers Most? Dementia and Pain in Nursing Home Patients: A Cross-sectional Study | 2.5 | 137 | Citations (PDF) |
| 478 | Clinical aspects of Parkinson dementia | 0.0 | 1 | Citations (PDF) |
| 479 | Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis | 4.1 | 37 | Citations (PDF) |
| 480 | Dementia in Parkinson's disease | 4.1 | 80 | Citations (PDF) |
| 481 | Are anxiety disorders undertreated in patients with multiple sclerosis? | 3.1 | 6 | Citations (PDF) |
| 482 | Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease | 2.0 | 86 | Citations (PDF) |
| 483 | FMR1 Alleles in Parkinson's Disease: Relation to Cognitive Decline and Hallucinations, A Longitudinal Study | 2.8 | 43 | Citations (PDF) |
| 484 | Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies | 1.2 | 157 | Citations (PDF) |
| 485 | Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms | 2.0 | 151 | Citations (PDF) |
| 486 | Subthreshold depression in patients with Parkinson's disease and dementia––clinical and demographic correlates | 2.4 | 18 | Citations (PDF) |
| 487 | Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group | 5.3 | 518 | Citations (PDF) |
| 488 | Clinical diagnostic criteria for dementia associated with Parkinson's disease | 5.3 | 2,838 | Citations (PDF) |
| 489 | Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force | 5.3 | 979 | Citations (PDF) |
| 490 | The effect of age of onset of PD on risk of dementia | 3.5 | 149 | Citations (PDF) |
| 491 | Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism | 3.3 | 61 | Citations (PDF) |
| 492 | Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation | 5.3 | 118 | Citations (PDF) |
| 493 | Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease | 2.4 | 100 | Citations (PDF) |
| 494 | Visual rating of white matter hyperintensities in Parkinson's disease | 5.3 | 100 | Citations (PDF) |
| 495 | Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease | 5.3 | 108 | Citations (PDF) |
| 496 | Changes in motor subtype and risk for incident dementia in Parkinson's disease | 5.3 | 405 | Citations (PDF) |
| 497 | Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia | 5.3 | 568 | Citations (PDF) |
| 498 | Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease | 5.3 | 301 | Citations (PDF) |
| 499 | Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community‐based, longitudinal study | 5.3 | 22 | Citations (PDF) |
| 500 | A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry | 2.0 | 244 | Citations (PDF) |
| 501 | Current perspectives in dementia with Lewy bodies | 0.4 | 1 | Citations (PDF) |
| 502 | Psychiatric aspects of Parkinsonʼs disease | 4.9 | 13 | Citations (PDF) |
| 503 | Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study | 6.5 | 319 | Citations (PDF) |
| 504 | A systematic review of prevalence studies of dementia in Parkinson's disease | 5.3 | 1,135 | Citations (PDF) |
| 505 | Psychiatric and behavioral symptoms in Alzheimer’s disease and other dementias: Etiology and management | 4.7 | 24 | Citations (PDF) |
| 506 | Role of Neuropsychiatric Assessment in Diagnosis and Research 2005, , 163-183 | | 0 | Citations (PDF) |
| 507 | Progression of motor impairment and disability in Parkinson disease | 1.2 | 255 | Citations (PDF) |
| 508 | Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study | 2.8 | 163 | Citations (PDF) |
| 509 | Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias | 2.9 | 194 | Citations (PDF) |
| 510 | Cognitive impairment and dementia in Parkinson's disease 2005, , 657-663 | | 0 | Citations (PDF) |
| 511 | Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies | 2.8 | 157 | Citations (PDF) |
| 512 | Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies | 5.2 | 323 | Citations (PDF) |
| 513 | Psychiatric Aspects of Parkinson’s Disease, Parkinson’s Disease with Dementia, and Dementia with Lewy Bodies | 2.8 | 3 | Citations (PDF) |
| 514 | Are Parkinson’s Disease with dementia and Dementia with lewy Bodies the Same Entity? | 2.8 | 188 | Citations (PDF) |
| 515 | Improvement in behavioral symptoms and advance of activity acrophase after short-term bright light treatment in severe dementia | 3.2 | 85 | Citations (PDF) |
| 516 | Dementia with Lewy bodies | 12.9 | 682 | Citations (PDF) |
| 517 | Psychiatric issues in non-Alzheimer dementias | 2.0 | 7 | Citations (PDF) |
| 518 | A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease | 2.4 | 107 | Citations (PDF) |
| 519 | Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia | 2.4 | 128 | Citations (PDF) |
| 520 | Psychiatric issues in non-Alzheimer dementias | 2.0 | 1 | Citations (PDF) |
| 521 | Rivastigmine for Dementia Associated with Parkinson's Disease | 25.1 | 1,188 | Citations (PDF) |
| 522 | The Rate of Cognitive Decline in Parkinson Disease | 5.2 | 247 | Citations (PDF) |
| 523 | Prevalence and Characteristics of Dementia in Parkinson Disease | 5.2 | 1,381 | Citations (PDF) |
| 524 | Basal ganglia diseases and geriatric psychiatry: a new approach | 4.9 | 1 | Citations (PDF) |
| 525 | The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease | 2.4 | 209 | Citations (PDF) |
| 526 | Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease | 2.4 | 170 | Citations (PDF) |
| 527 | Comparison of Extrapyramidal Signs in Dementia With Lewy Bodies and Parkinson's Disease | 2.4 | 78 | Citations (PDF) |
| 528 | A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia | 2.4 | 346 | Citations (PDF) |
| 529 | Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease | 2.4 | 148 | Citations (PDF) |
| 530 | Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study | 2.7 | 712 | Citations (PDF) |
| 531 | Prevalence and Clinical Correlates of Psychotic Symptoms in Parkinson Disease | 5.2 | 375 | Citations (PDF) |
| 532 | Neuropsychiatric aspects of parkinson’s disease | 6.3 | 58 | Citations (PDF) |
| 533 | Donepezil for dementia with Lewy bodies: a case study 1999, 14, 69-72 | | 65 | Citations (PDF) |
| 534 | Lexical and Nonlexical Spelling Deficits in Dementia of the Alzheimer Type | 2.1 | 19 | Citations (PDF) |
